Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Aberrant class switching juxtaposes c-myc with a middle repetitive element (LINE) and an IgH intron in two spontaneously arising rat immunocytomas

  • W S Pear
  • S F Nelson
  • H Axelson
  • G Wahlström
  • H Bazin
  • G Klein
  • J Sümegi
Publishing year: 1988-05
Language: English
Pages: 499-507
Publication/Series: Oncogene
Volume: 2
Issue: 5
Document type: Journal article
Publisher: Nature Publishing Group

Abstract english

Our previous studies of spontaneously arising rat immunocytomas of the Lou/Wsl strain have shown that Ig switch regions are frequently the targets for c-myc recombination. In several tumors, however, we were unable to show recombination of the c-myc with Ig switch regions. We have cloned the rearranged c-myc fragments from 2 of these tumors, IR209 and IR223, and found that the c-myc recombines with a LINE region in the IR209 and with intron 1 of the epsilon locus in the IR223. Although switch regions are not found at the breakpoints, the sequences at the breakpoints share limited homology with Ig switch recognition sequences. This suggests that the switch recombinase enzymes are able to recognize sequences in addition to the defined switch recombination sites. At the same time, both the LINE and epsilon intron 1 sequences are located within the Ig cluster, providing further evidence for the selection of c-myc activation by Ig sequences in the pathogenesis of rat immunocytoma, mouse plasmacytoma, and Burkitt's lymphoma.


  • Animals
  • Base Sequence
  • Genes, Immunoglobulin
  • Genes, Regulator
  • Genes, Switch
  • Immunoglobulin Heavy Chains
  • Immunoglobulin epsilon-Chains
  • Introns
  • Molecular Sequence Data
  • Plasmacytoma
  • Proto-Oncogene Proteins
  • Proto-Oncogenes
  • Rats
  • Repetitive Sequences, Nucleic Acid
  • Sequence Homology, Nucleic Acid
  • Translocation, Genetic


  • ISSN: 0950-9232
Håkan Axelson
E-mail: hakan [dot] axelson [at] med [dot] lu [dot] se


Division of Translational Cancer Research

+46 46 222 64 34

MV 404 A31A2